SB Sagimet Biosciences Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Sagimet Biosciences Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €648.3m. The latest transaction was disclosed on 17 August 2026 (Levée d'options). Among the most active insiders: Kemble George. Every trade is openly available.
Analyst consensus: bullish or bearish? Analysts rate Sagimet Biosciences Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$28.60.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 August 2026
All Executives48 Thresholds0 Prospectus0 Other0
Declarations 48 total
◇ Director · Executives · 14 Aug 2026
24,369 shares @ US$6.36 0.024% mcap 2.3% of flow Series A Common Stock SEC:0001193125-26-354018:1
◇ Director · Executives · 14 Aug 2026
326,618 shares @ US$6.36 0.32% mcap 30.9% of flow Series A Common Stock SEC:0001193125-26-354018:0
▼ Director · Executives · 14 Aug 2026
350,987 shares @ US$10.2328 0.55% mcap 53.5% of flow Series A Common Stock SEC:0001193125-26-354018:2
◇ Director · Executives · 11 Aug 2026
9,751 shares @ US$6.36 0.010% mcap 6.9% of flow Series A Common Stock SEC:0001193125-26-347407:0
◇ Director · Executives · 11 Aug 2026
10,455 shares @ US$6.36 0.011% mcap 7.5% of flow Series A Common Stock SEC:0001193125-26-347407:1
▼ Director · Executives · 11 Aug 2026
20,206 shares @ US$9.9548 0.034% mcap 22.5% of flow Series A Common Stock SEC:0001193125-26-347407:2
● Director · Executives · 11 Aug 2026
20,206 shares @ US$9.57 0.033% mcap 100.0% of flow Common SEC144:0001950047-26-007964
▼ Chief Legal & Admin. Officer · Executives · 20 Jul 2026
10,545 shares @ US$7.7603 0.017% mcap 36.0% of flow Series A Common Stock SEC:0001193125-26-312394:0
▼ Director · Executives · 20 Jul 2026
18,844 shares @ US$7.4575 0.029% mcap 25.2% of flow Series A Common Stock SEC:0001193125-26-312386:0
▼ President & CEO · Executives · 20 Jul 2026
64,051 shares @ US$7.7605 0.10% mcap 40.7% of flow Series A Common Stock SEC:0001193125-26-312397:0
◆ Chief Legal & Admin. Officer · Executives · 19 Feb 2026
44,000 shares 0Series A Common Stock SEC:0001104659-26-018196:0
◆ Chief Medical Officer · Executives · 19 Feb 2026
44,000 shares 0Series A Common Stock SEC:0001104659-26-018194:0
◆ President & CEO · Executives · 19 Feb 2026
128,000 shares 0Series A Common Stock SEC:0001104659-26-018193:0
◆ Chief Financial Officer · Executives · 19 Feb 2026
44,000 shares 0Series A Common Stock SEC:0001104659-26-018191:0
▼ Chief Financial Officer · Executives · 10 Feb 2026
1,312 shares @ US$5.3603 100.0% of flow Series A Common Stock SEC:0001104659-26-014277:0
▼ Chief Legal & Admin. Officer · Executives · 10 Feb 2026
2,622 shares @ US$5.3602 9.3% of flow Series A Common Stock SEC:0001104659-26-014266:0
▼ President & CEO · Executives · 10 Feb 2026
12,101 shares @ US$5.3603 8.6% of flow Series A Common Stock SEC:0001104659-26-014283:0
▼ Chief Medical Officer · Executives · 10 Feb 2026
3,640 shares @ US$5.3602 15.6% of flow Series A Common Stock SEC:0001104659-26-014272:0
▼ Executive Chairman · Executives · 20 Nov 2025
37,688 shares @ US$7.6942 69.0% of flow Series A Common Stock SEC:0001104659-25-115071:0
◆ Chief Legal & Admin. Officer · Executives · 4 Nov 2025
9,855 shares 0Series A Common Stock SEC:0001104659-25-107806:0
▼ President & CEO · Executives · 21 Jul 2025
65,478 shares @ US$9.1346 88.5% of flow Series A Common Stock SEC:0001104659-25-070017:0
▼ Chief Medical Officer · Executives · 21 Jul 2025
8,277 shares @ US$9.1346 73.1% of flow Series A Common Stock SEC:0001104659-25-070015:0
▼ General Counsel and CCO · Executives · 21 Jul 2025
10,780 shares @ US$9.1346 73.1% of flow Series A Common Stock SEC:0001104659-25-070013:0
◆ General Counsel and CCO · Executives · 6 Feb 2025
34,000 shares 0Series A Common Stock SEC:0001104659-25-010586:0
◆ President & CEO · Executives · 6 Feb 2025
116,000 shares 0Series A Common Stock SEC:0001104659-25-010587:0
25 of 48 declarations
Load more (23 remaining) 关于 Sagimet Biosciences Inc. Sagimet Biosciences Inc. 是一家生物制药公司，专注于开发代谢疾病的创新疗法。该公司在纳斯达克上市，股票代码为 SAGE。